The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Myosana Therapeutics raised $5 million in seed funding in January 2023 to advance an experimental gene-delivery platform, with Duchenne muscular dystrophy (DMD) as its first intended target. The company describes an antibody-guided approach to carry genetic payloads to muscle cells. Its reported mouse result was unpublished, and the available sources do not establish that a clinical candidate has been selected or that human testing has begun.
What Myosana is developing
Myosana’s proposed platform uses antibodies intended to bind a protein on skeletal and cardiac muscle cells and direct genetic payloads to those cells. The company’s initial target is DMD, a genetic disease for which the company said it wanted to develop a gene-delivery approach.
In the 2023 report, Myosana presented the platform as a possible way to deliver larger genes, including the full DMD gene, and potentially permit repeat administration. Those are proposed technical advantages, not established outcomes in patients. The company’s CEO, Matthew Lumley, said in the funding announcement, as quoted by GeekWire: “As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases.” That was a forward-looking statement, not evidence of successful treatment.
What the $5 million round funded
GeekWire reported on Jan. 25, 2023, that Myosana raised $5 million in a seed round led by John Ballantyne. The report attributed $650,000 to the Muscular Dystrophy Association and $500,000 to Parent Project Muscular Dystrophy. Parent Project Muscular Dystrophy had previously invested $350,480 in Myosana in August 2021, and CureDuchenne Ventures was also an earlier investor.
The University of Washington Neurobiology & Biophysics department posted a notice on Jan. 27, 2023, linking to the GeekWire story and Myosana’s funding announcement. The department’s post confirms institutional amplification of the news; it is not independent validation of the platform’s scientific claims. Myosana was launched in 2018 by UW researchers Stanley Froehner and Nick Whitehead. GeekWire reported that Froehner was chairman and Whitehead chief scientific officer; Lumley became CEO in January 2023.
How the proposed approach compares with AAV gene delivery
GeekWire described Myosana’s concept as non-viral and contrasted its proposed payload capacity and possible repeat dosing with limitations associated with adeno-associated virus (AAV) gene-delivery approaches. The distinctions below reflect the company’s and report’s descriptions, not comparative clinical evidence.
Rank #2
| Comparison | Myosana’s proposed antibody-directed platform | AAV-based gene delivery as described in the report |
|---|---|---|
| Payload | Company proposed delivering larger genes, including the full DMD gene; this has not been established as a clinical advantage. | GeekWire described AAV approaches as payload-limited, with some strategies using truncated dystrophin. This is not a claim about every DMD gene therapy. |
| Repeat administration | Possible repeat dosing is a proposed feature; it is not established in clinical use. | The report described immune responses as a limitation and noted that AAV approaches are generally designed for one-time use. |
| Evidence cited | GeekWire reported a mouse result but said the data were unpublished. | The cited report does not provide a comparable efficacy or safety assessment for AAV products. |
| Clinical status in the available sources | Myosana says it is progressing toward its first clinical candidate, without naming one. | The report does not establish a specific AAV product’s clinical status. |
These approaches should not be read as equally tested options or as evidence that Myosana’s platform is safer or more effective. The source material does not support a head-to-head comparison.
What the mouse result does—and does not—show
GeekWire reported that co-founder Nick Whitehead said the team had delivered the full DMD gene to muscles in mice through intravenous injection. The story explicitly noted that Myosana’s data were unpublished. The report therefore offers a company-reported preclinical claim, not independently assessable study results, human evidence, or demonstrated clinical benefit.
What is known about Myosana’s development timeline
In 2023, the company said the funding would help it identify an early development candidate by 2025. That was a target, not a confirmed milestone. Myosana’s current About page says it has completed two funding rounds and is progressing toward its first clinical candidate, but it does not name a candidate or confirm that the 2025 target was met. The available sources do not establish published efficacy or safety data or whether clinical trials have begun.
Quick Recap
Best Value
Rank #4
- Duchenne Muscular Dystrophy featuring a Green Boxing Gloves and text that reads "We Fight Together" to support for Duchenne Muscular Dystrophy warriors, Great idea for National Duchenne Muscular Dystrophy Awareness Month for men, women, and kids.
- Show your support for Duchenne Muscular Dystrophy Awareness wearing this motivational Quote We Fight Together hopefully to Extinct the Duchenne Muscular Dystrophy. great for Christmas, Birthday and Duchenne Action Month.
- Hardcover journal with 240 line-ruled pages (120 sheets)
- Built-in elastic closure and ribbon bookmark
- Includes an expandable inner storage pocket and a pen holder
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
